Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.
The trading halt, which began at 9:00 a.m. CEST on the same day, was implemented to facilitate the allocation process and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States. Each ADS represents one ordinary share with a nominal value of 鈧�0.01.
Abivax (Euronext Paris: ABVX), una societ脿 biotecnologica in fase clinica, ha annunciato la ripresa delle negoziazioni delle sue azioni ordinarie su Euronext Paris a partire dal 24 luglio 2025, alle 15:30 CEST.
La sospensione delle negoziazioni, iniziata alle 9:00 CEST dello stesso giorno, 猫 stata attuata per facilitare il processo di allocazione e l'annuncio del prezzo dell'offerta di American Depositary Shares (ADS) della societ脿 negli Stati Uniti. Ogni ADS rappresenta un'azione ordinaria con un valore nominale di 鈧�0,01.
Abivax (Euronext Paris: ABVX), una empresa biotecnol贸gica en fase cl铆nica, anunci贸 la reanudaci贸n de la negociaci贸n de sus acciones ordinarias en Euronext Paris a partir del 24 de julio de 2025, a las 15:30 CEST.
La suspensi贸n de la negociaci贸n, que comenz贸 a las 9:00 CEST del mismo d铆a, se implement贸 para facilitar el proceso de asignaci贸n y el anuncio del precio de la oferta de American Depositary Shares (ADS) de la compa帽铆a en Estados Unidos. Cada ADS representa una acci贸n ordinaria con un valor nominal de 鈧�0,01.
Abivax (Euronext Paris: ABVX)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 7鞗� 24鞚� 鞓ろ泟 3鞁� 30攵� CEST攵�韯� Euronext Paris鞐愳劀 氤错喌欤� 瓯半灅臧� 鞛皽霅潉 氚滍憸頄堨姷雼堧嫟.
霃欖澕頃� 雮� 鞓れ爠 9鞁� CEST攵�韯� 鞁滌瀾霅� 瓯半灅 欷戨嫧鞚� 氙戈淡鞐愳劀 須岇偓鞚� American Depositary Shares (ADS) 瓿惦鞚� 氚办爼 鞝堨皑 氚� 臧�瓴� 氚滍憸毳� 鞗愴櫆頃橁矊 頃橁赴 鞙勴暣 鞁滍枆霅橃棃鞀惦媹雼�. 臧� ADS電� 鞎‰┐臧� 鈧�0.01鞚� 氤错喌欤� 1欤茧ゼ 雮橅儉雰呺媹雼�.
Abivax (Euronext Paris : ABVX), une soci茅t茅 de biotechnologie en phase clinique, a annonc茅 la reprise de la cotation de ses actions ordinaires sur Euronext Paris 脿 compter du 24 juillet 2025 脿 15h30 CEST.
La suspension des 茅changes, d茅but茅e 脿 9h00 CEST le m锚me jour, a 茅t茅 mise en place pour faciliter le processus d鈥檃llocation et l鈥檃nnonce du prix de l鈥檕ffre des American Depositary Shares (ADS) de la soci茅t茅 aux 脡tats-Unis. Chaque ADS repr茅sente une action ordinaire d鈥檜ne valeur nominale de 0,01 鈧�.
Abivax (Euronext Paris: ABVX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, gab die Wiederaufnahme des Handels mit seinen Stammaktien an der Euronext Paris ab dem 24. Juli 2025 um 15:30 Uhr MESZ bekannt.
Der Handelsstopp, der am selben Tag um 9:00 Uhr MESZ begann, wurde eingerichtet, um den Zuteilungsprozess und die Bekanntgabe des Preises des American Depositary Shares (ADS)-Angebots des Unternehmens in den Vereinigten Staaten zu erleichtern. Jede ADS entspricht einer Stammaktie mit einem Nennwert von 鈧�0,01.
- None.
- Potential dilution for existing shareholders through ADS offering
Abivax announces trading resumption of its ordinary shares on Euronext Paris
PARIS, France, July 24, 2025 鈥� 02:30 p.m. (CEST) 鈥� Abivax SA (Euronext Paris: FR0012333284 鈥� ABVX) (鈥�Abivax鈥� or the 鈥�Company鈥�), a clinical-stage biotechnology company focused on developing therapeutics that harness the body鈥檚 natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30听p.m. CEST.
Trading of the ordinary shares of the Company was halted at the request of the Company on July 24, 2025 from 9:00 a.m. CEST in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share,
***
About Abivax
Abivax听is a clinical-stage biotechnology company focused on developing therapeutics that harness the body鈥檚 natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in听France听and听the United States, Abivax鈥檚 lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contacts:
| Abivax Investor Relations Patrick Malloy [email protected] +1 847 987 4878 | 听 |
***
Disclaimer
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FAQ
When will Abivax (ABVX) resume trading on Euronext Paris?
Why was Abivax (ABVX) stock trading halted?
What is the conversion ratio for Abivax's American Depositary Shares?
What is Abivax's main business focus?
